

Raymond C W Hutubessy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6838976/publications.pdf>

Version: 2024-02-01

65
papers

3,447
citations

218677

26
h-index

144013

57
g-index

69
all docs

69
docs citations

69
times ranked

4488
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness thresholds: pros and cons. Bulletin of the World Health Organization, 2016, 94, 925-930.	3.3	518
2	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 575-590.	13.7	421
3	Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation, 2003, 1, 8.	1.5	390
4	Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. The Lancet Global Health, 2014, 2, e406-e414.	6.3	194
5	WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine, 2010, 28, 2356-2359.	3.8	145
6	Cost effectiveness analysis of strategies for child health in developing countries. BMJ: British Medical Journal, 2005, 331, 1177.	2.3	126
7	The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Medicine, 2015, 13, 209.	5.5	106
8	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics, 2016, 34, 227-244.	3.3	97
9	Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health, 2012, 12, 878.	2.9	96
10	Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2018, 21, 1133-1149.	0.3	94
11	Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine, 2013, 31, 3786-3804.	3.8	91
12	A systematic review of the social and economic burden of influenza in low- and middle-income countries. Vaccine, 2015, 33, 6537-6544.	3.8	91
13	Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries. PLoS ONE, 2014, 9, e101114.	2.5	70
14	Influenza vaccines in low and middle income countries. Human Vaccines and Immunotherapeutics, 2013, 9, 1500-1511.	3.3	50
15	Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine, 2018, 36, 2529-2544.	3.8	49
16	Costs of Illness Due to Cholera, Costs of Immunization and Cost-Effectiveness of an Oral Cholera Mass Vaccination Campaign in Zanzibar. PLoS Neglected Tropical Diseases, 2012, 6, e1844.	3.0	46
17	Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Medicine, 2012, 10, 137.	5.5	46
18	A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. BMC Medicine, 2012, 10, 136.	5.5	45

#	ARTICLE	IF	CITATIONS
19	Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. PLoS ONE, 2017, 12, e0182663.	2.5	43
20	Guidelines for multi-model comparisons of the impact of infectious disease interventions. BMC Medicine, 2019, 17, 163.	5.5	39
21	Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Medicine, 2011, 9, 54.	5.5	37
22	Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Medicine, 2011, 9, 84.	5.5	34
23	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infectious Diseases, The, 2021, 21, 1598-1610.	9.1	34
24	A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. Vaccine, 2015, 33, 7357-7363.	3.8	33
25	Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?. Applied Health Economics and Health Policy, 2016, 14, 245-252.	2.1	32
26	Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, 2015, 33, A240-A247.	3.8	27
27	Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Medicine, 2011, 9, 55.	5.5	26
28	Global economic evaluations of rotavirus vaccines: A systematic review. Vaccine, 2017, 35, 3364-3386.	3.8	25
29	WHO guide on the economic evaluation of influenza vaccination. Influenza and Other Respiratory Viruses, 2018, 12, 211-219.	3.4	25
30	Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Medicine, 2013, 11, 23.	5.5	24
31	Critical issues in the economic evaluation of interventions against communicable diseases. Acta Tropica, 2001, 78, 191-206.	2.0	22
32	Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. Value in Health, 2018, 21, 1250-1258.	0.3	21
33	The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making. SSRN Electronic Journal, 0, , .	0.4	21
34	Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study. BMC Public Health, 2015, 15, 356.	2.9	19
35	Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Medicine, 2011, 9, 53.	5.5	18
36	Decision-making on malaria vaccine introduction: the role of cost-effectiveness analysis. Bulletin of the World Health Organization, 2012, 90, 864-866.	3.3	18

#	ARTICLE	IF	CITATIONS
37	A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme. <i>Vaccine</i> , 2021, 39, 412-422.	3.8	17
38	Maternal influenza immunization in Malawi: Piloting a maternal influenza immunization program costing tool by examining a prospective program. <i>PLoS ONE</i> , 2017, 12, e0190006.	2.5	16
39	Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. <i>Vaccine</i> , 2013, 31, 5430-5434.	3.8	15
40	Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries. <i>Health Affairs</i> , 2016, 35, 227-234.	5.2	15
41	Rationale and opportunities in estimating the economic burden of seasonal influenza across countries using a standardized WHO tool and manual. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 13-21.	3.4	15
42	Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. <i>Vaccine</i> , 2018, 36, 3993-3997.	3.8	15
43	Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. <i>Health Policy and Planning</i> , 2018, 33, 204-214.	2.7	14
44	Systematic Review on the Acute Cost-of-illness of Sepsis and Meningitis in Neonates and Infants. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 35-40.	2.0	14
45	Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework. <i>Pharmacoeconomics</i> , 2018, 36, 79-90.	3.3	13
46	Global economic evaluation of oral cholera vaccine: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 420-429.	3.3	13
47	Parent, provider and vaccinee preferences for HPV vaccination: A systematic review of discrete choice experiments. <i>Vaccine</i> , 2020, 38, 7226-7238.	3.8	12
48	WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. <i>BMC Medicine</i> , 2022, 20, 88.	5.5	12
49	Economic evaluation of seasonal influenza vaccination in elderly and health workers: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 47, 101410.	7.1	12
50	A Scoping Review of Investment Cases for Vaccines and Immunization Programs. <i>Value in Health</i> , 2019, 22, 942-952.	0.3	11
51	A review of the costs of delivering maternal immunisation during pregnancy. <i>Vaccine</i> , 2020, 38, 6199-6204.	3.8	9
52	The CAPACITI Decision-Support Tool for National Immunization Programs. <i>Value in Health</i> , 2021, 24, 1150-1157.	0.3	9
53	How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making. <i>Vaccine: X</i> , 2020, 6, 100078.	2.1	8
54	The case for assessing the full value of new tuberculosis vaccines. <i>European Respiratory Journal</i> , 2020, 55, 1902414.	6.7	8

#	ARTICLE	IF	CITATIONS
55	“It takes two to tango”: Bridging the gap between country need and vaccine product innovation. <i>PLoS ONE</i> , 2020, 15, e0233950.	2.5	7
56	Economic evaluations of <i>Haemophilus influenzae</i> type b (Hib) vaccine: a systematic review. <i>Journal of Medical Economics</i> , 2017, 20, 1094-1106.	2.1	6
57	Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool. <i>Vaccine</i> , 2022, 40, 1879-1887.	3.8	5
58	Costs of seasonal influenza vaccination in South Africa. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 873-880.	3.4	5
59	Rotavirus vaccines contribute towards universal health coverage in a mixed public-private healthcare system. <i>Tropical Medicine and International Health</i> , 2016, 21, 1458-1467.	2.3	4
60	Comparing 3 Approaches for Making Vaccine Adoption Decisions in Thailand. <i>International Journal of Health Policy and Management</i> , 2020, 9, 439-447.	0.9	4
61	Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong. <i>Vaccine</i> , 2021, 39, 6762-6780.	3.8	3
62	Identification and Prioritization of the Economic Impacts of Vaccines. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	2
63	Costing oral cholera vaccine delivery using a generic oral cholera vaccine delivery planning and costing tool (CholTool). <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3111-3118.	3.3	2
64	Assessing fitness-for-purpose and comparing the suitability of COVID-19 multi-country models for local contexts and users. <i>Gates Open Research</i> , 0, 5, 79.	1.1	1
65	Modeling anticipated changes in numbers of SARS-CoV-2 infections within communities due to immunization campaigns. <i>Gates Open Research</i> , 0, 6, 7.	1.1	1